Fujisawa and Roche Announce Co-Promotion of MYCAMINE

Fujisawa Healthcare and Roche Pharmaceuticals announced a partnership for the U.S. co-promotion of MYCAMINE (micafungin sodium) injection, Fujisawa's newly approved product for the treatment of patients with esophageal candidiasis and for the propylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. MYCAMINE, an antifungal in the echinocandin class, was approved by the US FDA on March 16, 2005. It is the first echinocandin approved for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Yahoo News (http://biz.yahoo.com/prnews/050331/nyth070r.html?.v=1)